Loading
Life sciences · Journal article
Avicenna Journal of Medical Biotechnology · October 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Dual‑positive EpCAM⁺/CD45⁺ ovarian cancer cells in malignant ascites are proposed as ovarian cancer stem-like cells, yet their cellular origin and trans-criptomic programs remain debated. Methods: In this work expression data from ascites‑derived EpCAM⁺/CD45⁺ dual‑ positive ovarian cancer stem‑like cells (DpOCSCs; GSE75036) and reference non‑ dual‑positive ovarian cancer stem cells (OCSCs; GSE90125, GSE216627) was in-tegrated. The workflow included cross‑platform harmonization, differential expression analysis, pathway enrichment, protein–protein interaction mapping, and evaluation in independent cohorts (TCGA, CPTAC, survival databases). Results: DpOCSCs showed 347 up‑regulated and 23 down‑regulated genes (|log₂FC|>1, FDR<0.1). Enrichment analyses revealed overrepresentation of interferon‑α/γ re-sponses, TNF, NF‑κB, IL‑6, JAK‑STAT3, and CXCR4 signaling, and pathways linked to natural killer cell‑mediated cytotoxicity, indicating a distinct inflammatory signature. Network analysis identified 17 up‑regulated hub genes; 10 had higher mRNA in ovarian tumors versus normal tissues (TCGA), and 3 (SYK, CD74, MX1) showed elevated pro-tein in CPTAC. In bulk ovarian cancer cohorts, these hubs were exploratorily associated with copy‑number amplifications, immune‑checkpoint expression, immunosuppressive infiltration, and clinicopathological features, including lymphatic/venous invasion and therapy outcomes. Survival and ROC analyses indicated context‑dependent associations of SYK, CD74, and MX1 with overall and progression‑free survival; SYK achieved an AUC ≈0.7 for predicting 6‑month relapse, particularly in paclitaxel‑treated patients. Transcription‑factor enrichment implicated Wnt/β‑catenin, Hippo, and NF‑κB as upstream regulators. Conclusion: These in silico findings are hypothesis‑generating and nominate a SYK‑associated inflammatory network for functional assessment in DpOCSCs and as a potential source of exploratory biomarkers for recurrent ovarian cancer.